Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 15/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423620 | 0.92 | GRIA2 (0.65) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1423747 | 0.88 | GRIA2 (0.81) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1423653 | 0.88 | GRIA2 (0.84) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1423711 | 0.87 | GRIA2 (0.66) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL3143259 | 0.86 | GRIA2 (0.78) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1424200 | 0.85 | GRIA2 (0.54) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1423813 | 0.85 | GRIA2 (0.62) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL13300519 | 0.84 | GRIA2 (0.71) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1423867 | 0.80 | GRIA2 (1.00) | GRIA2CYP2D6CYP2C9CYP1A2GAA | |
| SCHEMBL1423623 | 0.80 | GRIA2 (0.96) | GRIA2CYP2D6CYP2C9CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086643-B1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GRIN1, GRM2, GRIN3A | GRIA2 23/4885CYP2D6 1687/4885CYP2C9 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.